An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Exscientia plc (NASDAQ: EXAI) is set to release its third-quarter financial results for the period ending September 30, 2022, on November 15, 2022, before U.S. market openings. A conference call and webcast will follow at 1:30 p.m. GMT / 8:30 a.m. EST to discuss the results and provide a business update. Exscientia specializes in AI-driven drug discovery, focusing on precision oncology and other therapeutic areas, aiming to deliver innovative treatment solutions.
Positive
AI-driven approach to drug discovery, which could enhance efficiency and innovation.
Potential for significant advancements in oncology and other therapeutic areas through its precision medicine platform.
Negative
None.
Company to host conference call and webcast on November 15, 2022, at 1:30 p.m. GMT / 8:30 a.m. EST
OXFORD, England--(BUSINESS WIRE)--
Exscientia plc (Nasdaq: EXAI) will report financial results for the third quarter ended September 30, 2022, on Tuesday, November 15, 2022, before the open of U.S. markets. The Company will host a conference call and webcast at 1:30 p.m. GMT / 8:30 a.m. EST, to provide a business update and review financial results.
A webcast of the live call can be accessed by visiting the “Investors and Media” section of the Company’s website at investors.exscientia.ai. Alternatively, the live conference call can be accessed by dialing +1 (888) 330 3292 (U.S.), +44 203 433 3846 (U.K.), +1 (646) 960 0857 (International) and entering the conference ID: 8333895. A replay will be available for 90 days under "Events and Presentations” in the “Investors and Media” section of the Exscientia website.
About Exscientia
Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients.
Exscientia is headquartered in Oxford (England, U.K.), with offices in Vienna (Austria), Dundee (Scotland, U.K.), Boston (Mass., U.S.), Miami (Fla., U.S.), Cambridge (England, U.K.), and Osaka (Japan).
